PhRMA, the trade group representing brand-name drug makers in the U.S., has filed a lawsuit against the Trump administration over a Medicare pilot that ties U.S. drug prices to those paid in peer countries. The suit, filed October 7, asserts that the "most-favored-nation" pilot in Medicare Part B exceeds Medicare's statutory authority.

The program at issue, called GLOBE, is not expected to have much practical impact. The administration exempted all but a handful of companies in exchange for voluntary agreements to charge Medicaid most-favored-nation prices. But the industry sees a precedent it wants stopped now. PhRMA's position is precise: the voluntary agreements are acceptable, the mandatory GLOBE program is not.

That distinction matters for R&D portfolio planning. A voluntary Medicaid deal can be priced and negotiated. A mandatory benchmarking of Medicare Part B reimbursement against overseas prices sets a formula the industry cannot bargain over — and one that could, if it survives legal challenge, spread beyond the handful of non-exempt companies.

What does the lawsuit actually challenge?

PhRMA's core legal claim is statutory. The complaint argues the Centers for Medicare & Medicaid Services lacks the authority under existing law to impose international price referencing in Part B, the portion of Medicare that covers drugs administered in physician offices and clinics.

For laboratory and clinical operations, the stakes are concrete. Part B reimbursement shapes which therapies are economically viable in the community-administered setting — a channel that includes many oncology and biologic products. A pricing formula anchored to foreign prices would compress U.S. margins on those products, and portfolio decisions about which Part B-administered candidates to advance could shift accordingly.

The likely near-term effect, though, is limited. With nearly all major manufacturers exempted under the voluntary Medicaid deals, GLOBE's direct reach is narrow. The real fight is over the legal principle: whether the administration can construct mandatory international pricing mechanisms without new legislation. A court win for the government would open a door PhRMA prefers kept shut.

What is happening with restricted peptides?

Separately, the Trump administration is drafting plans that would permit the temporary sale of certain previously restricted peptides while federal health officials develop new regulations for these products, The Washington Post reported October 7.

The move would let some compounding pharmacies dispense peptides marketed as new medical treatments and wellness products — even though claims about what they treat have not been fully safety tested. The plan has not been announced, and its timing remains unclear. It could still change.

For research managers, the peptide story cuts two ways. Looser compounding access could expand demand for analytical services, potency testing and quality-control work around compounds that sit outside the approved-drug framework. It also means clinicians and consumers may be exposed to products whose safety claims rest on untested ground — a gap that clinical and regulatory teams will eventually have to close with data.

The two developments share a common thread: both move key pricing and access decisions out of the conventional approval-and-reimbursement pipeline and into administrative and legal channels. R&D and market-access teams should track the GLOBE litigation docket and any Federal Register notices on peptide compounding in the weeks ahead, since either could reset assumptions now embedded in commercial forecasts.